Ovarian cancer (OC) is the fifth leading cause of cancer death in women. High mortality rates are due to vague symptoms of early disease, leading to diagnosis at a late stage. Approximately 10% of OCs are considered hereditary. The KRAS-variant is an inherited, germline variant that has been demonstrated to serve as a genetic marker of increased risk of OC. The KRAS-variant is easily tested in a blood or saliva sample, and has been shown to be at a high prevalence in OC patients. This test could serve as an answer to patients with a family history of ovarian and breast cancer without a previously identifiable genetic mutation.
Keywords: Hereditary non-polyposis colorectal cancer; KRAS-variant; MicroRNA; Oncomirs; Ovarian cancer.
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20. Cancer Res. 2010. PMID: 20647319 Free PMC article.
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.PLoS One. 2012;7(5):e37891. doi: 10.1371/journal.pone.0037891. Epub 2012 May 25. PLoS One. 2012. PMID: 22662244 Free PMC article.
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.Oncologist. 1996;1(5):326-330. Oncologist. 1996. PMID: 10388011
Hereditary ovarian cancer.Crit Rev Oncol Hematol. 2009 Jan;69(1):28-44. doi: 10.1016/j.critrevonc.2008.06.003. Epub 2008 Jul 24. Crit Rev Oncol Hematol. 2009. PMID: 18656380 Review.
[Clinical and molecular diagnosis of inherited breast-ovarian cancer].J Gynecol Obstet Biol Reprod (Paris). 2003 Apr;32(2):101-19. J Gynecol Obstet Biol Reprod (Paris). 2003. PMID: 12717301 Review. French.
Cited by 1 article
Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.J Cell Physiol. 2014 Apr;229(4):393-406. doi: 10.1002/jcp.24466. J Cell Physiol. 2014. PMID: 24105793 Free PMC article. Review.